Board co-Chair, President and Chief Executive Officer · REGENERON PHARMACEUTICALS, INC. (REGN)

Leonard Schleifer

A named executive officer of REGENERON PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$7,280,549

FY2024: $6,823,034

4th of 6 named executive officers at Regeneron Pharmaceuticals by FY2025 total.

6 named officers on file for REGENERON PHARMACEUTICALS, FY2025

See an example →

What this number hides

The filing gives the total. REGENERON PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A).

Free

Get Leonard Schleifer’s full pay file as a PDF — free

More than this page: up to 10 years of Leonard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Leonard Schleifer and every company like it: Velarion Intel, free for 3 days, no card →

Leonard Schleifer compensation by year

REGENERON PHARMACEUTICALS Summary Compensation Table · all 10 fiscal years held
In US dollars, as REGENERON PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$1,242,000$1,285,500$1,330,500$1,377,100$1,480,119$1,767,800$1,811,995$1,875,415$1,941,100$1,979,922
Bonus$0$0$0$0$0$0$0$0$0$0
Stock awards$0$0$0$4,983,226$130,000,032$0$0$0$0—
Option awards$24,631,012$21,967,210$21,339,913$11,699,586$0$0$0$0$0—
Non-equity incentive$2,235,600$2,468,160$2,953,710$3,057,162$3,567,714$4,030,584$4,131,349$4,275,946$3,493,980$3,682,655
Pension and deferred compensation$0$0$0$0$0$0$0$0$0$0
All other$228,908$787,188$896,432$338,043$302,256$672,130$1,060,725$2,032,977$1,387,954$1,617,972
Total$28,337,520$26,508,058$26,520,555$21,455,117$135,350,121$6,470,514$7,004,069$8,184,338$6,823,034$7,280,549

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENERON PHARMACEUTICALS, INC. DEF 14A filed April 24, 2026, accession 0001308179-26-000340, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENERON PHARMACEUTICALS, INC. filed document, accession 0001308179-26-000340. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$28.3M
$26.5M
$26.5M
$21.5M
$135.4M
$6.5M
$7.0M
$8.2M
$6.8M
$7.3M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU620,270$441,836,929—

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENERON PHARMACEUTICALS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

REGENERON PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Daniel Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply$8,780,263
Andrew MurphyExecutive Vice President, Co-Chief Scientific Officer$8,477,119
Joseph LaRosaExecutive Vice President, General Counsel and Secretary$7,458,970
Leonard Schleifer · this pageBoard co-Chair, President and Chief Executive Officer$7,280,549
Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer$6,985,364
George YancopoulosBoard co-Chair, President and Chief Scientific Officer$6,949,469

Board service

REGENERON PHARMACEUTICALS board · FY2021–FY2025

How this board is paid

Company policy: REGENERON PHARMACEUTICALS pays directors a $90,000 cash retainer and $600,000 in Stock Options (80%) and RSUs (20%). As stated in REGENERON PHARMACEUTICALS's FY2025 proxy.

The full REGENERON PHARMACEUTICALS compensation record

free company brief

This page is one person within REGENERON PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the REGENERON PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order REGENERON PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENERON PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order REGN

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Leonard Schleifer's compensation dossier